企業プロフィール
NuCana plc 株価・ニュース・カタリスト
- ティッカー:
- NCNA
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United Kingdom
株価パフォーマンス
1.52 USD (-0.65%)
終値
最終更新: 2026年8月21日
8.62M USD
時価総額
株価変動の要因
As of Aug 21, 2026, NCNA closed down 0.65% at $1.52. No new same-company headline was identified in the current news window.
企業概要
ProTide Oncology Company
NuCana applies its ProTide chemistry platform to transform nucleoside analogs into medicines designed to generate higher concentrations of active anticancer metabolites inside tumor cells.
NUC-7738
NUC-7738 is a ProTide that disrupts RNA polyadenylation and affects multiple components of the tumor microenvironment. It is being evaluated with pembrolizumab in PD-1-inhibitor-resistant melanoma.
NUC-3373
NUC-3373 is a targeted thymidylate-synthase inhibitor designed to overcome pharmacologic limitations of established fluoropyrimidine therapies.
Combination Development
NuCana is evaluating tumor types and drug combinations that could support future registrational strategies for both NUC-7738 and NUC-3373.
今後のカタリスト
- Final data from the Phase 2 NuTide:701 expansion study of NUC-7738 in melanoma during 2026.
- FDA guidance on a potential registrational strategy for NUC-7738 in melanoma during 2026.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。